ライフサイエンスコーパス: interleukin-17

1 es, including interleukin-17A (also known as interleukin-17).

2 was characterized by its capacity to produce interleukin 17.

3 tory cytokines, such as interferon gamma and interleukin 17.

4 iting interleukin-23-dependent production of interleukin-17.

5 sease inflammation through the production of interleukin-17.

6 e-colony stimulating factor (G-CSF), but not interleukin-17.

7 alpha alone or in combination with CD40L or interleukin-17.

8 peutics, centered on naive T-cell depletion, interleukin-17/21 inhibition, kinase inhibition, regulat

9 ith ex vivo screening, and was essential for interleukin-17 A (IL-17A)-mediated cross-reactivity and

10 Interleukin 17(A) (IL-17) is a potent pro-inflammatory c

11 milder presentation had increasing levels of interleukin 17 and cytokines in the interferon-gamma/int

12 eased numbers of CD4(+) T cells that secrete interleukin 17 and interferon gamma, and caused CD11b(+)

13 Interleukin 17 and interleukin 1beta increased, whereas

14 robial defense in intestinal mucosa, through interleukin 17 and interleukin 22 (IL-22) production.

15 Notably, C. parapsilosis induced much less interleukin 17 and interleukin 22 production as compared

16 elated with increased inflammatory cytokines interleukin 17 and tumor necrosis factor-alpha but not g

17 cells was seen with increased expression of interleukin-17 and interleukin-22 by day 5 after injury.

18 n activated naive gammadelta T cells to make interleukin-17 and respond to cytokine signals that perp

19 trongly and selectively reduced secretion of interleukin-17 and tumor necrosis factor alpha by transf

20 ron gamma and tumor necrosis factor (but not interleukin 17), and lower production of T helper (Th)2

21 of the effector molecules interferon-gamma, interleukin-17, and interleukin-21.

22 terferon-gamma, tumor necrosis factor-alpha, interleukin-17, and interleukin-22.

23 and efficacy of LY2439821, a humanized anti-interleukin-17 (anti-IL-17) monoclonal antibody, in a fi

24 immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afford

25 th increased tumor necrosis factor-alpha and interleukin-17, as well as decreased transforming growth

26 ron-gamma), Th-2 (interleukin-4), and Th-17 (interleukin-17)-associated cytokines than wild-type mice

27 terleukin-6, interleukin-10, interleukin-12, interleukin-17) at day 1 and day 8.

28 of CD4+ Th17 T cells and the interleukin-23/interleukin-17 axis has challenged existing paradigms an

29 esponse and activation of the interleukin-23/interleukin-17 axis have been observed in animal models

30 Activation of the interleukin-23/interleukin-17 axis in spondyloarthritis has important t

31 ging data suggesting that the interleukin-23/interleukin-17 axis may be involved in the pathogenesis

32 tion studies suggest that the interleukin-23/interleukin-17 axis plays an important role in spondyloa

33 icate the evolution of both inflammatory and interleukin 17-based immune pathogenesis in GVHD, and pr

34 proteins: Compared with baseline, levels of interleukin-17, basic fibroblast growth factor, granuloc

35 iving the proliferation of and production of interleukin 17 by naive 139TCR cells in vitro and in viv

36 y correlated with a significant reduction in interleukin-17 by in vitro-restimulated splenocytes of T

37 oinflammatory cytokines interferon-gamma and interleukin-17 by lymph node T cells and later with incr

38 ration of responder tumors by CD8+ cells and interleukin-17+ cells, and decreased infiltration of res

39 and produced more interferon-gamma and less interleukin-17 compared to effector T cells.

40 Plasma transforming growth factor-beta and interleukin-17 concentrations were increased in T-bet(-/

41 is necessary for signaling by members of the interleukin-17 cytokine family.

42 gal burden, increased pulmonary Th1-type and interleukin-17 cytokine production, and classical macrop

43 anipulation of Th1 (interleukin-2) and Th17 (interleukin-17) cytokines.

44 isease may result from environments favoring interleukin-17-driven neutrophilia.

45 had increased T-cell activation markers and interleukin-17 expression compared to wild-type mice.

46 s and trigger a disproportionate increase in interleukin-17 expression in the brain.

47 ed disease is also associated with increased interleukin-17 expression, which may be due to suppressi

48 With the strong interleukin 17 family signature and the need to treat ea

49 Immune alterations include a strong interleukin 17 family signature as well as marked expres

50 The constituent polypeptides of the interleukin-17 family form six different homodimeric cyt

51 nd cytokines (interleukin-6, interleukin-10, interleukin-17, granulocyte-macrophage colony-stimulatin

52 cells, characterized by their production of interleukin-17, have emerged as important and broad medi

53 y of dendritic cells (DCs) and thus inhibits interleukin-17(+) helper T cells (Th17) immunity.

54 t subsets of gammadelta T cells that produce interleukin 17 (IL-17) (CD27(-) gammadelta T cells) or i

55 LTi cells also produce interleukin 17 (IL-17) and IL-22, signature cytokines se

56 llicles was partly dependent on the cytokine interleukin 17 (IL-17) and on the cell surface molecule

57 Here, we tested the hypothesis that interleukin 17 (IL-17) and tumor necrosis factor (TNF) a

58 oward a proinflammatory phenotype, producing interleukin 17 (IL-17) and/or interferon gamma (IFN-gamm

59 T helper cells that produce interleukin 17 (IL-17) are associated with inflammation

60 Interleukin 17 (IL-17) contributes to development of Th1

61 utants were associated with higher levels of interleukin 17 (IL-17) expression from lamina propria CD

62 Through the use of interleukin 17 (IL-17) fate-reporter mice, we found here

63 ber of studies have reported the presence of interleukin 17 (IL-17) in patients with Lyme disease, an

64 Dysregulated expression of interleukin 17 (IL-17) in the colonic mucosa is associat

65 As interleukin 17 (IL-17) is a critical cytokine in host de

66 Interleukin 17 (IL-17) is a signature cytokine of Th17 c

67 Interleukin 17 (IL-17) is an inflammatory cytokine that

68 ned to investigate whether the expression of interleukin 17 (IL-17) is associated with the indetermin

69 Interleukin 17 (IL-17) is critical in the pathogenesis o

70 Interleukin 17 (IL-17) is important in infection and aut

71 Instead, we found that interleukin 17 (IL-17) produced by CD4(+) T cells was es

72 rleukin 1beta (IL-1beta) release and reduces interleukin 17 (IL-17) production and bacterial clearanc

73 reflected by heightened interferon gamma and interleukin 17 (IL-17) production as well as by high lev

74 us bacteria (SFB), as well as an increase of interleukin 17 (IL-17) production by intestinal cells.

75 olites that inhibit T-cell proliferation and interleukin 17 (IL-17) production.

76 Interleukin 17 (IL-17) promotes the expression of chemok

77 ed to the variable effects of EHS on gastric interleukin 17 (IL-17) responses to H. pylori infection.

78 eron gamma, tumor necrosis factor alpha, and interleukin 17 (IL-17) were all significantly increased

79 tudy examines the ability of MAC to regulate interleukin 17 (IL-17), a proinflammatory cytokine invol

80 Although IFN-gamma, interleukin 17 (IL-17), and IL-22 were stimulated by the

81 make either interferon-gamma (IFN-gamma) or interleukin 17 (IL-17), but the role of the T cell antig

82 nd TH2 cytokines and increased production of interleukin 17 (IL-17), gamma interferon (IFN-gamma), CC

83 Interleukin 17 (IL-17)-committed gammadelta T cells (gam

84 Interleukin 17 (IL-17)-mediated immunity plays a key rol

85 Act1 is an essential adaptor in interleukin 17 (IL-17)-mediated signaling and is recruit

86 Interleukin 17 (IL-17)-producing CD4(+) helper T cells (

87 rently normal compartments of regulatory and interleukin 17 (IL-17)-producing CD4(+) T cells, as well

88 helper 17 (nTH17) cells are a population of interleukin 17 (IL-17)-producing cells that acquire effe

89 quisition of T helper type 1 (TH1) cell- and interleukin 17 (IL-17)-producing helper T (TH17) cell-li

90 Interleukin 17 (IL-17)-producing helper T cells (T(H)-17

91 gested to be important in the development of interleukin 17 (IL-17)-producing helper T cells (T(H)-17

92 Interleukin 17 (IL-17)-producing helper T cells (T(H)17

93 CD4(+) interleukin 17 (IL-17)-producing helper T cells (T(H)17

94 Interleukin 17 (IL-17)-producing helper T cells (T(H)17

95 factor BATF controls the differentiation of interleukin 17 (IL-17)-producing helper T cells (T(H)17

96 Interleukin 17 (IL-17)-producing helper T cells (T(H)17

97 mouse regulatory T cells (T(reg) cells) and interleukin 17 (IL-17)-producing helper T cells (T(H)17

98 Overactive responses by interleukin 17 (IL-17)-producing helper T cells (T(H)17

99 elitis (EAE) due to autoimmunity mediated by interleukin 17 (IL-17)-producing helper T cells (TH17 ce

100 Interleukin 17 (IL-17)-producing helper T cells (TH17 ce

101 BATF is required for the differentiation of interleukin 17 (IL-17)-producing helper T cells (TH17 ce

102 of segmented filamentous bacteria and fewer interleukin 17 (IL-17)-producing lamina propria T cells.

103 lls resemble the T helper type 1 (T(H)1) and interleukin 17 (IL-17)-producing T helper (T(H)17) subse

104 years ago, inducible regulatory T cells and interleukin 17 (IL-17)-producing T helper cells have bee

105 T(H)-17 cells are interleukin 17 (IL-17)-secreting CD4+ T helper cells inv

106 A subset of CD8(+) T cells can secrete interleukin 17 (IL-17).

107 FA-1, and by reciprocal higher expression of interleukin 17 (IL-17).

108 gammadelta T cell populations that produced interleukin 17 (IL-17).

109 of inflammatory CD4(+) T cells that produce interleukin-17 (IL-17) (termed Th17) has been identified

110 tumor necrosis factor alpha (TNF-alpha), and interleukin-17 (IL-17) after restimulation with LcrV and

111 ve been characterized based on production of interleukin-17 (IL-17) and association with autoimmune d

112 Interleukin-17 (IL-17) and IL-17 receptor (IL-17R) signa

113 n of murine Th17 cells and the production of interleukin-17 (IL-17) and IL-21, two cytokines associat

114 immune responses, via its ability to produce interleukin-17 (IL-17) and IL-21.

115 controlling the production and functions of interleukin-17 (IL-17) and IL-22, cytokines that direct

116 inally reported to produce cytokines such as interleukin-17 (IL-17) and IL-22, we demonstrate here th

117 TH17 responses, including the expression of interleukin-17 (IL-17) and IL-22.

118 Serum Interleukin-17 (IL-17) and IL-23 correlate with active d

119 jor sources of the proinflammatory cytokines interleukin-17 (IL-17) and interferon-gamma (IFNgamma) i

120 ssion of the pro-inflammatory cytokine genes interleukin-17 (IL-17) and macrophage migration inhibito

121 Levels of gastric interleukin-17 (IL-17) and tumor necrosis factor alpha (

122 Antibody-mediated blockade of interleukin-17 (IL-17) as well as the receptor for IL-23

123 Secretion of interleukin-17 (IL-17) by PBMCs was measured by enzyme-l

124 Several groups have recently reported that interleukin-17 (IL-17) confers protection against the li

125 It is not known whether interleukin-17 (IL-17) cytokines, which regulate inflamm

126 Interleukin-17 (IL-17) deficiency in mice or humans lead

127 us macaques, we show that the suppression of interleukin-17 (IL-17) expression correlated with upregu

128 roduction, which is accompanied by sustained interleukin-17 (IL-17) expression that persists even aft

129 otype of pathologic IVD specimens, including interleukin-17 (IL-17) expression, from surgically obtai

130 acterized by their unique ability to secrete interleukin-17 (IL-17) family cytokines.

131 Cytokines of the interleukin-17 (IL-17) family have been proposed as impo

132 Although several interleukin-17 (IL-17) family members and their receptor

133 The interleukin-17 (IL-17) family of cytokines (IL-17A to IL

134 Th17-like immune responses mediated by the interleukin-17 (IL-17) family of cytokines and neutrophi

135 The interleukin-17 (IL-17) family of cytokines has emerged a

136 The interleukin-17 (IL-17) family of cytokines phylogenetica

137 The interleukin-17 (IL-17) family of cytokines plays importa

138 Although interleukin-17 (IL-17) has been linked to human lupus an

139 Since interleukin-17 (IL-17) has been reported to play a patho

140 Interleukin-17 (IL-17) has emerged as a key cytokine inv

141 A major role for the cytokine interleukin-17 (IL-17) has now been described in various

142 emergence of Th17 cells and higher levels of interleukin-17 (IL-17) in lung tissue, which were reduce

143 the role of T helper type 17 responses, and interleukin-17 (IL-17) in particular, has been controver

144 has been reported that ectopically expressed interleukin-17 (IL-17) in tumor cells suppresses tumor p

145 ltrating T helper type 17 (T(H)17) cells and interleukin-17 (IL-17) induced the expression of granulo

146 Interleukin-17 (IL-17) induces pathology in autoimmunity

147 Interleukin-17 (IL-17) is a critical pro-inflammatory cy

148 Interleukin-17 (IL-17) is a major pro-inflammatory cytok

149 Interleukin-17 (IL-17) is a pivotal T cell cytokine in a

150 Interleukin-17 (IL-17) is a proinflammatory cytokine sec

151 Interleukin-17 (IL-17) is crucial for the progression of

152 Interleukin-17 (IL-17) is essential in host defense agai

153 The proinflammatory cytokine interleukin-17 (IL-17) is involved in neutrophilic tissu

154 The importance of interleukin-17 (IL-17) is underscored both by its resist

155 d produced a "closed" chromatin structure at interleukin-17 (IL-17) locus to inhibit Th17 cell functi

156 f patients with select gene disruptions, the interleukin-17 (IL-17) pathway has emerged as a critical

157 capability of human CD4(+) T cells to become interleukin-17 (IL-17) producers.

158 cell assays showed reduced proliferation and interleukin-17 (IL-17) production by lymph node cells fr

159 ollowing experimental challenge and impaired interleukin-17 (IL-17) production by vaccine antigen-sti

160 the DCs that were generated induced enhanced interleukin-17 (IL-17) production from naive CD4+ T cell

161 CD4+ T cells, enhanced interferon-gamma and interleukin-17 (IL-17) production, and elevated levels o

162 ted and control mice were unable to suppress interleukin-17 (IL-17) production.

163 Interleukin-17 (IL-17) promotes the response of neutroph

164 neither CXC chemokine receptor 2 (CXCR2) nor interleukin-17 (IL-17) receptor (IL-17R) deficiency chan

165 functional CD4(+) T cells, signaling via the interleukin-17 (IL-17) receptor, and IL-22 production.

166 emonstrated an enhanced innate expression of interleukin-17 (IL-17) relative to wild-type (WT) mice.

167 Interleukin-17 (IL-17) released in the tumor microenviro

168 ate the role of DCs in the H. pylori-induced interleukin-17 (IL-17) response.

169 Interleukin-17 (IL-17) secreted by T helper 17 (Th17) ce

170 Interleukin-17 (IL-17) secreted by T helper 17 cells and

171 growth-related oncogene alpha (GROalpha) and interleukin-17 (IL-17) than did infection with the serot

172 show that growth factor FGF2 synergized with interleukin-17 (IL-17) to induce genes for repairing of

173 f mRNAs for gamma interferon (IFN-gamma) and interleukin-17 (IL-17) was found to be temporarily upreg

174 However, elevated levels of interleukin-17 (IL-17) were present in infected lymph no

175 Spleen Th17 cells and joint interleukin-17 (IL-17) were quantified by fluorescence-a

176 ndothelium and epithelium, and overexpressed interleukin-17 (IL-17) with massive neutrophilic inflamm

177 CD4(+) interleukin-17 (IL-17)(+) T cells (Th17 cells) have been

178 high levels of the proinflammatory cytokine interleukin-17 (IL-17), accompanied by an induction of I

179 cate that Tregs have the capacity to produce interleukin-17 (IL-17), although the ability of these ce

180 nhibited CD154 expression, interferon-gamma, interleukin-17 (IL-17), and IL-6 production, and T cell-

181 with significant decreases in the levels of interleukin-17 (IL-17), gamma interferon, tumor necrosis

182 opulations, interferon-gamma (IFN-gamma) and interleukin-17 (IL-17), have been shown to play a critic

183 ssociated with decreased local production of interleukin-17 (IL-17), IL-18, and tumor necrosis factor

184 et (TH17), characterized by the secretion of interleukin-17 (IL-17), in disease pathogenesis.

185 isease, and immunoablated T cells expressing interleukin-17 (IL-17), interferon-gamma and tumor necro

186 Gammadelta T cells are an innate source of interleukin-17 (IL-17), preceding the development of the

187 Interleukin-17 (IL-17), the prototype cytokine produced

188 y cytokines gamma interferon (IFN-gamma) and interleukin-17 (IL-17), which are regulated by IL-12 and

189 On the other hand, interleukin-17 (IL-17), which is coexpressed with IL-22

190 to control infection, including the role of interleukin-17 (IL-17), which is important in controllin

191 Interleukin-17 (IL-17), which is predominantly produced

192 e in T helper 17 (Th17) cells and heightened interleukin-17 (IL-17)-dependent inflammation in experim

193 own that cells and cytokines associated with interleukin-17 (IL-17)-driven inflammation are involved

194 tor (TCR)gammadelta(+) T cells, including an interleukin-17 (IL-17)-expressing population.

195 terized by the early and sustained influx of interleukin-17 (IL-17)-positive neutrophils and macropha

196 s of helper T cells are the proinflammatory, interleukin-17 (IL-17)-producing (Th17) cells and the an

197 reg cells are converted into proinflammatory interleukin-17 (IL-17)-producing cells by inflammatory m

198 iotic exposure of dams reduced the number of interleukin-17 (IL-17)-producing cells in the intestine

199 Interleukin-17 (IL-17)-producing helper T (TH) cells, na

200 Interleukin-17 (IL-17)-producing helper T cells play a r

201 TH17 cells (interleukin-17 (IL-17)-producing helper T cells) are hig

202 alance between regulatory T (Treg) cells and interleukin-17 (IL-17)-producing T helper (TH17) cells;

203 For example, HIV preferentially depletes interleukin-17 (IL-17)-producing T helper 17 (Th17) cell

204 Interleukin-17 (IL-17)-producing T helper cells have bee

205 Interleukin-17 (IL-17)-secreting CD8(+) T cells have bee

206 cells (Tgammadelta17) are a major source of interleukin-17 (IL-17).

207 ta1(+) subset that is an important source of interleukin-17 (IL-17).

208 or necrosis factor alpha (TNF-alpha) but not interleukin-17 (IL-17).

209 um levels of immunoglobulin A (IgA), AMA and interleukin-17 (IL-17).

210 levels of inflammatory cytokines, including interleukin-17 (IL-17).

211 XCL1 and CCL2) and proinflammatory cytokine (interleukin 17 [IL-17]) expression in tissues surroundin

212 lature, and increased inflammation in brain (interleukin-17 [IL-17] and IL-6) and liver (gamma interf

213 aarticular cytokine expression (P < 0.01 for interleukin-17 [IL-17] and P < 0.001 for IL-23), and dec

214 on [IFN-gamma], tumor necrosis factor [TNF], interleukin-17 [IL-17], and IL-1beta) or chemokine (CXCL

215 Th17 cells (interleukin-17 [IL-17]-secreting T helper cells) have be

216 t optimal transcription of the gene encoding interleukin 17 (Il17) required a 2-kilobase promoter and

217 y owing to impaired interleukin 23-dependent interleukin 17 immunity.

218 Inborn errors of interleukin-17 immunity have recently been shown to unde

219 oduction of interferon gamma (IFN-gamma) and interleukin 17 in patients with an active retinochoroida

220 nhanced survival and increased production of interleukin-17 in conjunction with gamma-interferon.

221 roles of the cytokines interferon-gamma and interleukin-17 in determining the localization of inflam

222 scin-C-null mice displayed ablated levels of interleukin-17 in the joint during experimental arthriti

223 this issue of Immunity, Lin et al. implicate interleukin-17 in the regulation of T helper 1 (Th1) cel

224 rleukin 1beta, interleukin 6, interleukin 8, interleukin 17, interferon gamma, and tumor necrosis fac

225 at MCAM(+) CD8(+) T lymphocytes express more interleukin 17, interferon gamma, granulocyte-macrophage

226 tokines released from these cells, including interleukin-17, interferon-gamma, tumor necrosis factora

227 d unique approximately 200-fold expansion of interleukin 17+/interleukin 22+ T effectors with profoun

228 leukin-12/interleukin-23p40, interleukin-13, interleukin-17, interleukin-18, interferongamma, transfo

229 A landmark study has revealed that an interleukin-17-like signaling system modulates a neural

230 nterleukin-5, interleukin-7, interleukin-13, interleukin-17, macrophage inflammatory protein 1alpha a

231 nterleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophage inflammatory proteins-1alpha,

232 Inhibition of interleukin-23 and interleukin-17 may have a role in the management of LAD1

233 of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatm

234 Use of a humanized anti-interleukin-17 monoclonal antibody, ixekizumab, improved

235 Furthermore, an interleukin-17-neutralizing antibody attenuated OX40-med

236 In particular, the interferon gamma and interleukin 17 pathways are strongly induced in previous

237 egulatory T cells (Tregs) and demonstrate an interleukin-17 phenotype that enhances OC activation.

238 Neutralization of interleukin-17 prevented arthritis development in specif

239 e case in a study of the recently discovered interleukin-17 producing helper T cells (Th17), which ar

240 Interleukin 17-producing CD161high CCR6+ gammadelta T ce

241 Percentages of interleukin 17-producing cells were significantly higher

242 n of T helper type 2 cells (T(H)2 cells) and interleukin 17-producing helper T cells (T(H)17 cells) b

243 Interleukin 17-producing helper T cells (T(H)17 cells) h

244 mechanisms underlying the differentiation of interleukin 17-producing T helper cells (T(H)-17 cells)

245 Although recent discovery of the interleukin 17-producing T(H)-17 lineage appeared to sup

246 helper-1, T helper-17, and interferon-gamma/interleukin-17-producing CD4 T cells.

247 Recently, interleukin-17-producing CD4(+) T cells (Th17 cells) hav

248 cking the differentiation and/or function of interleukin-17-producing CD4(+) T cells on human autoimm

249 Interleukin-17-producing CD4(+) T helper (T(H)17) cells

250 interferon-gamma appear to be distinct from interleukin-17-producing cells, while in humans cells se

251 elp explain the flexibility and diversity of interleukin-17-producing cells.

252 ent had no detectable effect on Th1 cells or interleukin-17-producing gamma/delta T cells.

253 Here we demonstrate the critical role of interleukin-17-producing marrow infiltrating lymphocytes

254 n (MOG(35-55))-specific interferon-gamma and interleukin-17-producing T cells in experimental autoimm

255 ntibody levels increased, and IFN-gamma- and interleukin-17-producing T cells, including cells specif

256 of MOG(35-55)-specific interferon-gamma- and interleukin-17-producing T cells.

257 isms that prevent inappropriate or excessive interleukin-17-producing T helper (Th17) cell responses

258 le of STAT3 in regulating differentiation of interleukin-17-producing Th17 cells, but its function in

259 e staining demonstrated interferon gamma and interleukin 17 production and lack of interleukin 10 pro

260 Conversely, minimal interleukin 4 and interleukin 17 production was detected.

261 cal-specific T-cell interferon-gamma but not interleukin 17 production.

262 -linked immunospot assay as well as in vitro interleukin-17 production as predictors of vaccination s

263 als is required to suppress pro-inflammatory interleukin-17 production by intestinal immune cells and

264 i-NKG2D treatment significantly reduced both interleukin-17 production from CD4+ T cells in arthritic

265 is more important at later stages promoting interleukin-17 production.

266 n receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression.

267 dalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, random

268 rly clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab

269 Here, we showed that amplified signaling of interleukin-17 receptor B (IL-17RB) and its ligand IL-17

270 IL-17B and IL-25, both binding to the interleukin-17 receptor B (IL-17RB), were upregulated in

271 , we describe a role for the orphan receptor interleukin-17 receptor D (IL-17RD) in negatively regula

272 safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for the tre

273 this organism elicited a commensal-specific interleukin-17 response from gammadelta T cells in the o

274 ere necessary for the propagation of de novo interleukin-17 responses, and activated T cells from MS

275 g both T-bet and Eomes differentiate into an interleukin-17-secreting lineage, reminiscent of the hel

276 reover, the DB fusion in LDAO induced higher interleukin-17 secretion and provided a higher protectiv

277 tial cytokine production in macrophages, and interleukin 17 signaling.

278 ntigen presentation, chemokine activity, and interleukin-17 signaling.

279 impaired inflammatory responses and reduced interleukin-17 signalling during oropharyngeal candidias

280 d previously found a dominant interleukin-23-interleukin-17 signature at inflamed sites in humans wit

281 antibody titers, higher interferon gamma and interleukin 17 splenic responses, and more multifunction

282 These findings demonstrate that interleukin-17 T cells are critical to the genesis of my

283 differentiated into T helper cells producing interleukin 17 (T(H)-17 cells).

284 T-helper cells that produce interleukin-17 (T(H)17 cells) are a recently identified

285 CD4(+) T helper lymphocytes that express interleukin-17 (T(H)17 cells) have critical roles in mou

286 o that of pro-inflammatory T cells producing interleukin-17 (T(H)17).

287 ed for induction of T-helper cells producing interleukin-17 (Th17 cells) and important in antifungal

288 wofold more gamma-interferon (IFN-gamma) and interleukin-17 than nondiabetic lymphocytes.

289 d fewer lymphocytes and more neutrophils and interleukin-17 than WT mice.

290 lpha, interleukin 1beta, interleukin 12, and interleukin 17; the chemokines CCL2, CCL4, and CXCL10; a

291 d in the pretreated probiotic group, whereas interleukin 17 transcription was suppressed with probiot

292 ed less interferon gamma, interleukin 4, and interleukin 17 upon coculture with B cells from schistos

293 ced increased levels of interferon-gamma and interleukin-17 upon stimulation in vitro.

294 sessed by production of interferon gamma and interleukin 17, was preserved in the mucosa of patients

295 Further, whole lung levels of interleukin-17 were lower in allergic TLR9(-/-) mice com

296 okines (interleukin-2, interferon-gamma, and interleukin-17) when CD73 was lacking.

297 oduce cytokines such as interferon gamma and interleukin 17, which facilitate macrophage activation a

298 tial to produce the proinflammatory cytokine interleukin-17, which has been linked to transplant reje

299 ed to as LDb mice) exhibited increased serum interleukin-17, which was associated with increased numb

300 CL9, CXCL10, and CXCL11), interleukin-6, and interleukin-17 with significantly higher levels of Th17